Researchers have recently reported that multivitamins and selenium could greatly delay progression of HIV infection in people, who have not started using medicines.
Journal of the American Medical Association (JAMA)
HIV refers to human immunodeficiency virus. It disables immune system resulting in AIDS (Acquired immunodeficiency syndrome).
In the present study, researchers worked on nearly 900 HIV-infected patients in Africa. They divided the patients into groups. One group received placebo treatment, i.e. they took chemicals with no active ingredients, other group received multivitamins, including B, C and E vitamins. Another group received multivitamins and selenium, and still another group received only selenium.
Researchers studied the groups and found that basic multivitamins and selenium supplements could significantly decrease the chances of immune decline and morbidity, thereby greatly delay the progression of HIV infection. They reported that 32 out of 217 suffered progression of disease in the placebo treatment while 17 out of 220 suffered progression in the vitamin/mineral combination group. Multivitamins alone and selenium alone showed almost the same results as presented by placebo treatment.
“24-month supplementation with a single supplement containing multivitamins and selenium was safe and significantly reduced the risk of immune decline and morbidity. Micronutrient supplementation may be effective when started in the early stages of HIV disease,” Researchers concluded.
This research could become the basis of low-cost basis of future therapeutic strategies, not only for AIDS but also for other immunodeficiency disorders.
You can precede this study with other immunodeficiency disorders. Moreover, researchers have worked on supplementation without medicines, so you can work on supplementation with medicines, if possible.
Marianna K. Baum et al. (2013). Effect of Micronutrient Supplementation on Disease Progression in Asymptomatic, Antiretroviral-Naive, HIV-Infected Adults in Botswana
A Randomized Clinical Trial JAMA DOI: 10.1001/jama.2013.280923